No Clinically Significant Interaction Between Inactivated Influenza Vaccine and Topical Cyclosporine Eye Drops
There is no clinically significant interaction between the inactivated influenza vaccine and cyclosporine 0.05% ophthalmic emulsion (Restasis), and both can be safely administered together.
Key Evidence and Reasoning
Topical vs. Systemic Immunosuppression
The critical distinction here is the route of administration and systemic absorption:
- Cyclosporine ophthalmic emulsion (0.05%) is applied topically to the eye surface with minimal to negligible systemic absorption 1
- The drug acts as a local immunomodulator on the ocular surface to treat dry eye disease
- This is fundamentally different from systemic cyclosporine used in transplant recipients
Guideline Recommendations for Immunosuppressed Patients
The ACIP guidelines clearly distinguish between levels of immunosuppression when making vaccine recommendations:
- Live attenuated influenza vaccine (LAIV) is contraindicated in patients with immunosuppression, including those receiving immunosuppressive medications 2, 3
- Inactivated influenza vaccine (IIV) is safe and recommended for immunocompromised patients 3, 4
- The 2013 IDSA guidelines specifically state that inactivated vaccines should not be withheld from patients with chronic inflammatory diseases on immunosuppression 3
Why This Interaction is Not Relevant
Topical cyclosporine eye drops do not create systemic immunosuppression that would warrant special vaccine considerations:
- The contraindications for LAIV specifically reference systemic immunosuppression from medications 2, 5, 2
- Patients using topical cyclosporine are not considered immunocompromised for vaccination purposes
- The drug label for cyclosporine ophthalmic emulsion contains no warnings about vaccine interactions 1
Historical Context on Vaccine-Drug Interactions
While vaccine-drug interactions have been documented, they involve different mechanisms:
- Reported interactions with influenza vaccine involve drugs metabolized by hepatic cytochrome P-450 (warfarin, theophylline, phenytoin) 6
- These interactions occur through vaccine-induced interferon affecting drug metabolism
- Topical cyclosporine does not undergo significant hepatic metabolism and would not be subject to this mechanism
Research Evidence
Recent research on cyclosporine and influenza provides additional context:
- Studies examining systemic cyclosporine show it can modulate inflammatory responses to influenza infection 7
- However, this research involves systemic administration at immunosuppressive doses
- Ocular adverse events after influenza vaccination are rare and not related to topical cyclosporine use 8, 9
Clinical Recommendation
Proceed with inactivated influenza vaccination without any timing modifications or special precautions in patients using cyclosporine 0.05% ophthalmic emulsion:
- No need to hold or adjust the eye drop schedule
- No need to delay vaccination
- Use standard inactivated influenza vaccine (not LAIV, though LAIV would be inappropriate for other reasons if the patient has underlying conditions)
- Follow routine vaccination timing and administration guidelines 2
Important Caveats
Do not confuse topical ophthalmic cyclosporine with systemic cyclosporine:
- Patients on systemic cyclosporine (for transplant, severe autoimmune disease) require different considerations
- Those patients should receive inactivated influenza vaccine (preferably high-dose or adjuvanted formulations) but must avoid LAIV 3, 4
- Always verify the formulation and indication when reviewing a patient's medication list
The only influenza vaccine contraindication relevant to this scenario would be if the patient had a history of severe allergic reaction to influenza vaccine components or eggs (though egg allergy is no longer an absolute contraindication with appropriate precautions) 10.